|
|
|
|
| LEADER |
03394nmm a2200337 u 4500 |
| 001 |
EB002142019 |
| 003 |
EBX01000000000000001280145 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
230201 ||| eng |
| 020 |
|
|
|a 9789811955587
|
| 100 |
1 |
|
|a Rahman, Mahfoozur
|e [editor]
|
| 245 |
0 |
0 |
|a Hormone Related Cancer Mechanistic and Nanomedicines
|h Elektronische Ressource
|b Challenges and Prospects
|c edited by Mahfoozur Rahman, Waleed H Almalki, Majed Alrobaian, Sarwar Beg, Khalid S Alharbi
|
| 250 |
|
|
|a 1st ed. 2022
|
| 260 |
|
|
|a Singapore
|b Springer Nature Singapore
|c 2022, 2022
|
| 300 |
|
|
|a XIV, 347 p. 1 illus
|b online resource
|
| 505 |
0 |
|
|a Chapter 1. Conventional Treatment Approaches in Hormonal Cancer Treatment and Challenges -- Chapter 2. Concept of Nanomedicine in Endocrine Hormone Cancer Treatment -- Chapter 3. Progress of Cancer Nanomedicine, Clinical Hurdles and Opportunities -- Chapter 4. Emergence of Nanohybrids in Hormonal Cancer Targeted Therapy -- Chapter 5. Conventional to Nanoscale-Based Carrier System in Management of Ovarian Cancer -- Chapter 6. Pancreatic Cancer Nanoparticles Targeted Therapy via Epidermal Growth Factor Receptor -- Chapter 7. Nanocarriers Based Targeted Therapies for Pancreatic Cancer and Challenges Ahead -- Chapter 8. Pancreatic Cancer Treatment by Using of Theranostics Nanoparticles -- Chapter 9. Nanomedicine Based Combinational Therapy for Breast Cancer -- Chapter 10. Nano-Liposomal System for Breast Cancer Therapy -- Chapter 11. Conventional to Nanotherapeutic Strategies against Triple-Negative Breast Cancer -- Chapter 12. Effect of Thymoquinone and Its Delivery Through Using of Nanomedicine inBenign Prostatic Hyperplasia -- Chapter 13. Concept of Nanotechnology in Management of Neuroendocrine Tumours -- Chapter 14. Neurocognitive Underpinning of Neurological Disorders: The Role of Default Mode Network -- Chapter 15. Neuroendocrine Carcinoma of The Endometrium: Conventional Treatment Approach to Nanomedicine -- Chapter 16. Effective Luteinizing Hormone Drug Delivery by Gold Nanoparticles in Hormonal Cancer Treatment -- Chapter 17. Regulatory Landscapes in Approval of Cancer Vaccines
|
| 653 |
|
|
|a Cancers
|
| 653 |
|
|
|a Hormones
|
| 653 |
|
|
|a Cancer
|
| 653 |
|
|
|a Hormone
|
| 653 |
|
|
|a Oncology
|
| 700 |
1 |
|
|a H Almalki, Waleed
|e [editor]
|
| 700 |
1 |
|
|a Alrobaian, Majed
|e [editor]
|
| 700 |
1 |
|
|a Beg, Sarwar
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 028 |
5 |
0 |
|a 10.1007/978-981-19-5558-7
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-981-19-5558-7?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.994
|
| 520 |
|
|
|a The nanotheranostics sector provides a very promising strategy for monitoring drug biodistribution and pathology longitudinal processes by integrating the imaging and drug delivery functions in one single nanoformulation, providing vital insights into the identification of tumour and predicting the efficacy of nanomedicine. For its unique properties, which include their small size and biocompatibility and ability to permeate the cellular membrane with carrying drugs, nanomaterials have been used for various biomedical applications. This book covers the progress made in hormone-related cancer and their management by nonmedicinal therapy for targeting the hormone regulated cancer with their clinical progress and clinical hurdles
|